Biogen Inc

NASDAQ:BIIB   10:16:38 AM EDT
224.57
-1.34 (-0.59%)
Products

Biogen, Eisai Anticipate Submitting Final Protocol For Phase 4 Aduhelm Study For Review To U.S. FDA In March 2022

Published: 12/16/2021 13:27 GMT
Biogen Inc (BIIB) - Biogen - Co, Eisai Anticipate Submitting Final Protocol for Phase 4 Aduhelm Study for Review to U.S. FDA in March 2022.
Biogen - Co, Eisai Anticipate First Patient to Be Screened in Phase 4 Aduhelm Study in May 2022.
Further Company Coverage: Biibo ((reuters.
Briefs@thomsonreuters.
Com;)).